Lifeboat Foundation

Nearly two in five U.S. adults have high cholesterol, according to the Centers for Disease Control and Prevention (CDC). Untreated, high cholesterol can lead to heart disease and stroke, which are two of the top causes of death in the U.S. Worldwide; cardiovascular diseases claim nearly 18 million lives every year, according to the World Health Organization.

A new vaccine developed by researchers at The University of New Mexico School of Medicine could be a game-changer, providing an inexpensive method to lower “bad” LDL cholesterol, which creates dangerous plaques that can block blood vessels.

In a recent study published in npj Vaccines, a team led by Bryce Chackerian, Ph.D., Regents’ Professor in the Department of Molecular Genetics & Microbiology, reported the vaccines lowered LDL cholesterol almost as effectively as an expensive class of drugs known as PCSK9 inhibitors.

Welcome for another episode of Health Theory! This episode promises to deliver a riveting conversation with the master of fitness, Andy Galpin. Andy is not just your average exercise physiologist, professor, and researcher. He’s a true powerhouse with a trademark ability to seamlessly bridge the gap between academic knowledge and real-world application.

Europe’s health regulator followed the US and UK in backing the first gene-editing therapy to use Crispr technology, a Vertex Pharmaceuticals Inc. and Crispr Therapeutics AG treatment for sickle cell disease.

The European Medicines Agency’s expert panel recommended on Friday authorizing the Vertex and Crispr drug, Casgevy, for people with severe sickle cell disease and another serious hereditary blood disorder, beta-thalassemia, which is traditionally treated with repeated transfusions. Vertex said before the ruling that it had yet to establish a European list price for the one-time therapy, which costs $2.2 million in the US.

The treatment makes precisely targeted changes in patients’ DNA, a months-long process that requires removing bone marrow and a stem cell transplant. In Europe, Vertex said its initial focus will be on countries with the highest numbers of patients, including France, Italy, the UK and Germany.

Bad things can happen when you hallucinate. If you are human, you can end up doing things like putting your underwear in the oven. If you happen to be a chatbot or some other type of artificial intelligence (AI) tool, you can spew out false and misleading information, which—depending on the info—could affect many, many people in a bad-for-your-health-and-well-being type of way. And this latter type of hallucinating has become increasingly common in 2023 with the continuing proliferation of AI. That’s why Dictionary.com has an AI-specific definition of “hallucinate” and has named the word as its 2023 Word of the Year.

Dictionary.com noticed a 46% jump in dictionary lookups for the word “hallucinate” from 2022 to 2023 with a comparable increase in searches for “hallucination” as well. Meanwhile, there was a 62% jump in searches for AI-related words like “chatbot”, “GPT”, “generative AI”, and “LLM.” So the increases in searches for “hallucinate” is likely due more to the following AI-specific definition of the word from Dictionary.com rather than the traditional human definition:

hallucinate [ h uh-loo-s uh-neyt ]-verb-(of artificial i ntelligence) to produce false information contrary to the intent of the user and present it as if true and factual. Example: When chatbots hallucinate, the result is often not just inaccurate but completely fabricated.

Continue reading “Dictionary.com 2023 Word Of The Year ‘Hallucinate’ Is An AI Health Issue” »

WASHINGTON, Dec 14 (Reuters) — Twenty-eight healthcare companies, including CVS Health (CVS.N), are signing U.S. President Joe Biden’s voluntary commitments aimed at ensuring the safe development of artificial intelligence (AI), a White House official said on Thursday.

The commitments by healthcare providers and payers follow those of 15 leading AI companies, including Google, OpenAI and OpenAI partner Microsoft (MSFT.O) to develop AI models responsibly.

Biden’s government is pushing to set parameters around AI as it makes rapid gains in capability and popularity while regulation remains limited.

Elucidating human contact networks could help predict and prevent the transmission of SARS-CoV-2 and future pandemic threats. A new study from Scripps Research scientists and collaborators points to which public health protocols worked to mitigate the spread of COVID-19—and which ones didn’t.

In the study, published online in Cell on December 14, 2023, the Scripps Research-led team of scientists investigated the efficacy of different mandates—including stay-at-home measures, social distancing and travel restrictions —at preventing local and regional transmission during different phases of the COVID-19 pandemic.

They found that local transmission was driven by the amount of travel between locations, not by how geographically nearby they were. The study also revealed that the partial closure of the U.S.-Mexico border was ineffective at preventing cross-border transmission of the virus. These findings, in combination with ongoing genomic surveillance, could help guide public health policy to prevent future pandemics and mitigate the new “endemic” phase of COVID-19.

In a novel study, researchers from the Icahn School of Medicine at Mount Sinai have introduced LoGoFunc, an advanced computational tool that predicts pathogenic gain and loss-of-function variants across the genome.

Unlike current methods that predominantly focus on loss of function, LoGoFunc distinguishes among different types of harmful mutations, offering potentially valuable insights into diverse disease outcomes. The findings are described in Genome Medicine.

Genetic variations can alter protein function, with some mutations boosting activity or introducing new functions (gain of function), while others diminish or eliminate function (loss of function). These changes can have significant implications for human health and the treatment of disease.

A study published in the journal Physical Review Letters by researchers in Japan solves a long-standing problem in quantum physics by redefining the uncertainty principle.

Werner Heisenberg’s uncertainty principle is a key and surprising feature of quantum mechanics, and he can thank his hay fever for it. Miserable in Berlin in the summer of 1925, the young German physicist vacationed on the remote, rocky island of Helgoland, in the North Sea off the northern German coast. His allergies improved, and he was able to continue his work trying to understand the intricacies of Bohr’s model of the atom, developing tables of internal atomic properties, such as energy, position and momentum.

Continue reading “Extending the uncertainty principle by using an unbounded operator” »

This Perspective reviews large-scale genomics and longitudinal phenomics efforts and the insights they can provide into wellness. The authors describe their vision for the transformation of the current health care from disease-oriented to data-driven, wellness-oriented and personalized population health.